Chilean Prunes Support Muscle Mass
New Delhi [India], August 4: Chilean prunes, known for their digestive health benefits, are also a rich source of nutrients that support muscle growth, fat loss, and enhance energy levels, all while contributing to better cognitive health.
Recent research conducted at Oklahoma State University has revealed that regular consumption of prunes can significantly increase levels of IGF-1, a key protein that regulates growth hormone and supports the development of muscle and bone tissue. In the study, participants experienced a 17% increase in IGF-1, underscoring prunes potential in naturally promoting lean muscle growth.
Kavita Devgan, renowned dietitian, holistic health consultant, and acclaimed author said, "Just 5-6 prunes before a workout can provide the natural energy, thanks to their blend of natural sugars, fructose and glucose and high fibre content. They also promote better blood flow and satiety, making them a perfect pre-workout snack".
Mr. Sumit Saran, India Representative of Chilean prunes remarked, "Chile is known as one of the world's largest growers and suppliers of prunes. Chilean prunes are recognized globally for their high quality. Just visit your dry fruit retailer or head to the grocery store and ask for Chilean prunes."
Whether blended into smoothies, enjoyed on their own, or incorporated into both sweet and savoury dishes, Chilean prunes are a versatile, tasty way to fuel fitness goals naturally.
For further information, please contact: https://chileprunes.cl/?lang=en
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
an hour ago
- Economic Times
Novo Nordisk CEO warns of layoffs as Wegovy challenge heats up
Synopsis Novo Nordisk warned of ongoing competition from copycat versions of its obesity drug Wegovy and signaled possible layoffs due to slowing sales growth, especially in the U.S. The Danish drugmaker, which lost $95 billion in market value after cutting full-year forecasts, said over one million Americans still use compounded GLP-1 drugs despite a U.S. ban. Reuters Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could face layoffs as it battles rising pressure from main U.S. rival Eli Lilly, the Danish drugmaker warned on Wednesday. Novo, which became Europe's most valuable company worth $650 billion last year on booming sales of Wegovy, is facing a pivotal moment as the medicine loses market share and sees sales growth slow, especially in the United States. It has warned of far slower growth this year - in part due to compounders who have been allowed to make copycat medicines based on the same ingredients as Wegovy due to shortages. Novo cut its full-year sales and profit forecasts last week, wiping $95 billion off its market value since. The shares were down 3.4% at 1350 GMT. The slide is a huge and abrupt turnaround for the firm that has been one of the world's hottest investment stories, which led to a rapid expansion of manufacturing and sales capacity. Now the firm is eyeing potential cost-cutting measures. "We probably won't be able to avoid layoffs," outgoing CEO Lars Fruergaard Jorgensen told Danish broadcaster DR. "When you have to adjust a company, there are some areas where you have to have fewer people, some (areas) where you have to be smaller." He added, though, that any decision on layoffs would be in the hands of the incoming CEO, company veteran Maziar Mike Doustdar, who takes over on Thursday. On a media call, Jorgensen said the market for copycat versions of Wegovy's class of drugs - known as GLP-1 receptor agonists - was of "equal size to our business" and compounded versions of Wegovy were sold at a "much lower price point". In May, the company said it expected many of the roughly one million U.S. patients using compounded GLP-1 drugs to switch to branded treatments after a U.S. Food and Drug Administration ban on compounded copies of Wegovy took effect on May 22, and it expected compounding to wind down in the third quarter. However, finance chief Karsten Munk Knudsen said on Wednesday that more than one million U.S. patients were still using compounded GLP-1s and that Novo's lowered outlook has "not assumed a reduction in compounding" this year. "The obesity market is volatile," Knudsen told analysts when asked under what circumstances the company could see negative growth in the last six months of the year. The low end of Novo's new full-year guidance range would be for "unforeseen events", such as stronger pricing pressure in the U.S. than forecast, he said. The lower end of the range would imply sales around 150 billion Danish crowns ($23 billion) in the second half of 2025, compared with 157 billion in the same period last year. ENCOURAGING PRESCRIPTION DATA Knudsen reiterated that the company was pursuing multiple strategies, including lawsuits against compounding pharmacies, to halt unlawful mass compounding. Jorgensen said the company was encouraged by the latest U.S. prescription data for Wegovy. While the drug was overtaken earlier this year by rival Lilly's Zepbound in terms of U.S. prescriptions, that lead has narrowed in the past month. Second-quarter sales of Wegovy rose by 36% in the U.S. and more than quadrupled in markets outside the U.S. compared to a year ago, Novo said. While Wegovy's U.S. pricing held steady in the quarter, the company expected deeper erosion in the key U.S. market in the second half, due to a greater portion of sales expected from the direct-to-consumer or cash-pay channel, as well as higher rebates and discounts to insurers, Knudsen said. He said Novo was expanding its U.S. direct-to-consumer platform, NovoCare, launched in March, and may need to pursue similar "cash sales" directly to patients, outside of insurance channels, in some markets outside the United States. COST CUTS The company reiterated its full-year earnings expectations on Wednesday after last week's profit warning. Jorgensen said Novo was acting to "ensure efficiencies in our cost base" as the company announced it would terminate eight R&D projects. "There seems to be a larger R&D clean-out than usual, but we do not know if this reflects a strategic re-assessment or just a coincidence," Jefferies analysts said in a note. Investors have questioned whether Novo can stay competitive in the booming weight-loss drug market. Several equity analysts have cut their price targets and recommendation on the stock since last week. Shares in Novo plunged 30% last week - their worst weekly performance in over two decades. Sales rose 18% in the second quarter to 76.86 billion Danish crowns, below analysts' initial expectations.
Time of India
2 hours ago
- Time of India
Novo Nordisk CEO warns of layoffs as Wegovy challenge heats up
Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could face layoffs as it battles rising pressure from main U.S. rival Eli Lilly , the Danish drugmaker warned on Wednesday. Novo, which became Europe's most valuable company worth $650 billion last year on booming sales of Wegovy, is facing a pivotal moment as the medicine loses market share and sees sales growth slow, especially in the United States. Productivity Tool Zero to Hero in Microsoft Excel: Complete Excel guide By Metla Sudha Sekhar View Program Finance Introduction to Technical Analysis & Candlestick Theory By Dinesh Nagpal View Program Finance Financial Literacy i e Lets Crack the Billionaire Code By CA Rahul Gupta View Program Digital Marketing Digital Marketing Masterclass by Neil Patel By Neil Patel View Program Finance Technical Analysis Demystified- A Complete Guide to Trading By Kunal Patel View Program Productivity Tool Excel Essentials to Expert: Your Complete Guide By Study at home View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program It has warned of far slower growth this year - in part due to compounders who have been allowed to make copycat medicines based on the same ingredients as Wegovy due to shortages. Novo cut its full-year sales and profit forecasts last week, wiping $95 billion off its market value since. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Affordable Pre-Owned Jewelry in Great Condition in Malaysia Rings | Search Ads Search Now Undo The shares were down 3.4% at 1350 GMT. The slide is a huge and abrupt turnaround for the firm that has been one of the world's hottest investment stories, which led to a rapid expansion of manufacturing and sales capacity. Now the firm is eyeing potential cost-cutting measures. Live Events "We probably won't be able to avoid layoffs," outgoing CEO Lars Fruergaard Jorgensen told Danish broadcaster DR. "When you have to adjust a company, there are some areas where you have to have fewer people, some (areas) where you have to be smaller." He added, though, that any decision on layoffs would be in the hands of the incoming CEO, company veteran Maziar Mike Doustdar, who takes over on Thursday. On a media call, Jorgensen said the market for copycat versions of Wegovy's class of drugs - known as GLP-1 receptor agonists - was of "equal size to our business" and compounded versions of Wegovy were sold at a "much lower price point". In May, the company said it expected many of the roughly one million U.S. patients using compounded GLP-1 drugs to switch to branded treatments after a U.S. Food and Drug Administration ban on compounded copies of Wegovy took effect on May 22, and it expected compounding to wind down in the third quarter. However, finance chief Karsten Munk Knudsen said on Wednesday that more than one million U.S. patients were still using compounded GLP-1s and that Novo's lowered outlook has "not assumed a reduction in compounding" this year. "The obesity market is volatile," Knudsen told analysts when asked under what circumstances the company could see negative growth in the last six months of the year. The low end of Novo's new full-year guidance range would be for "unforeseen events", such as stronger pricing pressure in the U.S. than forecast, he said. The lower end of the range would imply sales around 150 billion Danish crowns ($23 billion) in the second half of 2025, compared with 157 billion in the same period last year. ENCOURAGING PRESCRIPTION DATA Knudsen reiterated that the company was pursuing multiple strategies, including lawsuits against compounding pharmacies, to halt unlawful mass compounding. Jorgensen said the company was encouraged by the latest U.S. prescription data for Wegovy. While the drug was overtaken earlier this year by rival Lilly's Zepbound in terms of U.S. prescriptions, that lead has narrowed in the past month. Second-quarter sales of Wegovy rose by 36% in the U.S. and more than quadrupled in markets outside the U.S. compared to a year ago, Novo said. While Wegovy's U.S. pricing held steady in the quarter, the company expected deeper erosion in the key U.S. market in the second half, due to a greater portion of sales expected from the direct-to-consumer or cash-pay channel, as well as higher rebates and discounts to insurers, Knudsen said. He said Novo was expanding its U.S. direct-to-consumer platform, NovoCare, launched in March, and may need to pursue similar "cash sales" directly to patients, outside of insurance channels, in some markets outside the United States. COST CUTS The company reiterated its full-year earnings expectations on Wednesday after last week's profit warning. Jorgensen said Novo was acting to "ensure efficiencies in our cost base" as the company announced it would terminate eight R&D projects. "There seems to be a larger R&D clean-out than usual, but we do not know if this reflects a strategic re-assessment or just a coincidence," Jefferies analysts said in a note. Investors have questioned whether Novo can stay competitive in the booming weight-loss drug market. Several equity analysts have cut their price targets and recommendation on the stock since last week. Shares in Novo plunged 30% last week - their worst weekly performance in over two decades. Sales rose 18% in the second quarter to 76.86 billion Danish crowns, below analysts' initial expectations.
Time of India
10 hours ago
- Time of India
6 health benefits of pine nuts: Know its nutritional compounds and safety tips
Pine nuts, also known as chilgoza, are nutrient-dense edible seeds that deliver not only rich, buttery flavor but also a host of health benefits. Packed with heart-healthy monounsaturated fats, plant-based protein, fibre, and essential minerals like magnesium, zinc, vitamin E, and vitamin K, they support overall well-being. Emerging evidence suggests pine nuts may help ease inflammation and joint discomfort, making them a beneficial addition for people with arthritis. In traditional remedies, pine nuts are valued for its natural anti-inflammatory properties. Incorporating pine nuts into your diet may promote heart health, blood sugar control, improved cognition, and even joint wellness, all while offering delicious macro- and micro-nutrient support. Why pine nuts are a superfood: From arthritis relief to immunity boost 1. Arthritis relief and anti‑inflammatory benefits Pine nuts contain pinolenic acid and antioxidants, such as vitamin E and polyphenols, that help reduce inflammation and joint pain, potentially easing arthritis symptoms. Traditional medicine and preliminary studies suggest symptom relief and improved joint mobility with regular consumption of nuts rich in anti‑inflammatory compounds. Their magnesium and zinc content also supports immune modulation and connective tissue health. Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like AirSense 11 – Smart tech for deep sleep ResMed Buy Now Undo by Taboola by Taboola 2. Heart health and cholesterol control The unsaturated fats and pinolenic acid in pine nuts help: Lower LDL (bad cholesterol) and triglycerides Increase HDL (good cholesterol) Eating 3 servings of pine nuts per week may support cardiovascular health through improved lipid metabolism and antioxidant protection 3. Blood sugar regulation and weight management High fibre, protein, and magnesium content help stabilize blood glucose, enhance insulin sensitivity, and promote fullness. The special acid pinolenic acid stimulates hunger-suppressing hormones, such as GLP‑1, helping curb appetite and support weight management 4. Brain, skin and bone support 5. Digestive and immune health Dietary fibre in pine nuts supports gut motility, eases constipation, and promotes microbiome balance. Minerals like zinc, copper, and manganese bolster immune defense and reduce oxidative damage system-wide 6. Eye health Pine nuts contain lutein, a powerful carotenoid that helps protect the eyes from oxidative stress and harmful blue light. Regular intake may lower the risk of age-related macular degeneration (AMD) and support overall visual health as you age. Why pine nuts are so healthy: Nutritional compounds Pine nuts are rich in: Healthy fats: Monounsaturated and polyunsaturated fatty acids (including omega‑6 pinolenic acid) that support heart health by lowering LDL cholesterol and raising HDL levels Protein & fiber: Help with satiety, weight control, stable blood sugar, and digestive health Essential vitamins and minerals: Vitamin E, vitamin K, B‑complex vitamins, magnesium, manganese, phosphorus, iron, zinc, and copper, supporting immunity, bone strength, skin health, and metabolic function Potential downsides and safety tips Pine mouth syndrome: A rare condition causing temporary metallic or bitter taste lasting up to two weeks in some individuals after consumption Allergies: Nut allergies may trigger hives, swelling, vomiting, or even anaphylaxis in sensitive individuals, exercise caution if you have known nut sensitivities Calorie density: Due to their high fat content, moderate portion sizes are important to avoid excess calorie intake and unwanted weight gain How to incorporate pine nuts into your diet Toast and sprinkle over salads or roasted vegetables Blend into pesto sauces, dressings, or hummus Add to oatmeal, granola, or yogurt parfaits Include in baked goods, cookies, breads, or energy bars Use pine nut oil as a flavourful dressing or cooking oil Also read | Cinnamon vs cardamom: Which spice is healthier and better for your diet, blood sugar and more
